Aegerion Pharmaceuticals, Inc. ("Aegerion") engages in the development of therapeutics and pharmaceuticals to treat cardiovascular and metabolic diseases.

According to a law firm's press release, on June 14, 2016, Aegerion’s Board of Directors (the “Board”) caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of Parent common stock. The Complaint alleges that on August 8, 2016, Defendants issued materially incomplete and misleading disclosures in the Form S-4 Registration Statement filed with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Registration Statement is deficient and misleading in that it fails to provide adequate disclosure of all material information related to the Proposed Transaction.

This case was voluntarily dismissed on December 27, 2016.